OpenNashPodcasts

Person

George Yancopoulos

This page collects what George Yancopoulos said on The Long Run with Luke Timmerman, a podcast episode about Regeneron Pharmaceuticals, its medicines and its approach to drug discovery. Each fact below comes with his exact quote and a link to the moment.

Yancopoulos talked about Regeneron's first approved drug, its antibody mice, and products such as Eylea and Dupixent. He also described the company's plan to stay independent, its plan to sequence the exomes of the 500,000-person UK Biobank, and his argument that the NIH budget should be far larger.

1 episodes · 18 quoted claims

George Yancopoulos said the FDA approved 22 medicines in 2016, of which only eight were first in class.

“Last year, 2016, 22 medicines approved by the FDA. Only eight of them. Only eight of them first in class.”

The Long Run with Luke Timmerman · 0:09:04

George Yancopoulos said he and his mentor Fred Alt first proposed making mice that produce human antibodies in 1985.

“it was my mentor Fred Ault and I in 1985 that actually made the first proposal to make these mice that could make human antibodies.”

The Long Run with Luke Timmerman · 0:10:25

Regeneron Pharmaceuticals had an important collaboration with Medarex, a company that also developed human antibody mice.

“And we actually collaborated. We had an important collaboration with Medarex.”

The Long Run with Luke Timmerman · 0:10:25

Yancopoulos said Len Schleifer helped create a business plan for Regeneron to stay independent, unlike other antibody companies that aimed to be acquired.

“he helped create a business plan and structure where we would stay independent. Whereas a lot of these other companies, their goal was to sort of get bought out.”

The Long Run with Luke Timmerman · 0:11:12

Regeneron Pharmaceuticals had two manufacturing plants, one in Rensselaer, New York and one in Limerick, Ireland.

“where we now have two plants, one up at Ronsolier and one in Ireland, in Raheem in Ireland.”

The Long Run with Luke Timmerman · 0:17:29

Regeneron Pharmaceuticals announced an initiative to sequence the exomes of the 500,000-person UK Biobank.

“We just recently announced a major initiative where we're going to be sequencing the UK biobank of 500 ,000 people.”

The Long Run with Luke Timmerman · 0:28:09

Yancopoulos said Regeneron's first drug approval was its IL-1 trap for cold-induced inflammatory syndrome, which he described as an early example of going from a human genetic disease to a blocking biologic.

“Our first drug approval, which is our IL-1 trap or ARKELIST in cold-induced inflammatory syndrome, was perhaps the first example”

The Long Run with Luke Timmerman · 0:29:22

Yancopoulos said the IL-1 trap produced an 85 percent average improvement in patients with cold-induced inflammatory syndrome.

“85 % average improvement in a horrific disease. That's how you want genes to work.”

The Long Run with Luke Timmerman · 0:30:03

Yancopoulos said Regeneron's PCSK9 antibody was the first approved anti-PCSK9 agent for lowering cholesterol, building on gene discoveries by Helen Hobbs and Jonathan Cohen at UT Southwestern.

“where we got the first approved anti-PCSK9 agent for lowering cholesterol”

The Long Run with Luke Timmerman · 0:30:03

Yancopoulos said Regeneron's head-to-head trials showed Eylea could be injected half as often as Lucentis with comparable results.

“We actually showed head to head that we can inject half as frequently and get as good data.”

The Long Run with Luke Timmerman · 0:37:01

Yancopoulos said the National Eye Institute ran side-by-side studies comparing Eylea with Lucentis and Avastin, and that Eylea beat them by one to two lines on an eye chart.

“the National Eye Institute and the National Institutes of Health did side-by-side studies, which are rarely done”

The Long Run with Luke Timmerman · 0:38:09

Yancopoulos said Dupixent launched in atopic dermatitis, a field with no other biologics.

“we priced in a brand new space. There was no other biologics for atopidermatitis.”

The Long Run with Luke Timmerman · 0:38:57

Yancopoulos said Dupixent was priced at less than half the average price of psoriasis drugs.

“we price our drug at less than half the price of the average psoriasis drugs just because we think it's the appropriate thing to do.”

The Long Run with Luke Timmerman · 0:39:29

Yancopoulos said the U.S. invests about $30 billion in the NIH budget and argued it should be at least an order of magnitude larger for basic research.

“It's a little silly from my perspective that we're investing as a nation $30 billion to attack what are arguably some of the most important challenges we have”

The Long Run with Luke Timmerman · 0:42:36

Yancopoulos said Nobel Prize winners Michael Brown and Joseph Goldstein, members of Regeneron's board, have worked together since the 1970s.

“Brown and Goldstein, Nobel Prize winners that have been working together since the 70s.”

The Long Run with Luke Timmerman · 0:47:28

Yancopoulos said Regeneron Pharmaceuticals had 250 interns in the summer of the interview, and the head of the Regeneron Genetics Center began as an intern.

“I think that this summer we had 250 interns.”

The Long Run with Luke Timmerman · 0:53:10

Yancopoulos said he and Len Schleifer are alumni of the Science Talent Search, which Regeneron sponsors.

“So many of us, including Len and I, are actual alumni of that program.”

The Long Run with Luke Timmerman · 0:53:58

Yancopoulos said Pfizer failed in late-stage phase three trials of a PCSK9 drug after spending billions of dollars.

“Pfizer, in a late stage, phase three trials stage after they spent billions, they failed, which shows how hard this business is.”

The Long Run with Luke Timmerman · 0:34:31